The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt-Reference-Cited by-同舟云学术

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

Published:2011-05-25 Issue:19 Volume:30 Page:2409-2421
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Royston Patrick,Parmar Mahesh K. B.

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/sim.4274/fullpdf

Reference19 articles.

1. Tables of the number of patients required in clinical trials using the logrank test;Freedman;Statistics in Medicine,1982

2. Sample-size formula for the proportional-hazards regression model;Schoenfeld;Biometrics,1983

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;New England Journal of Medicine,2009

4. The estimation of average hazard ratios by weighted Cox regression;Schemper;Statistics in Medicine,2009

5. Estimation of the average hazard ratio;Kalbfleisch;Biometrika,1981

Cited by 386 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial;European Respiratory Journal;2024-09

2. Hazard Ratios and Alternative Effect Measures: An Applied Illustration;Pharmacoepidemiology and Drug Safety;2024-08-30

3. A nonparametric framework for treatment effect modifier discovery in high dimensions;Journal of the Royal Statistical Society Series B: Statistical Methodology;2024-08-21

4. Reply to P. de Boissieu et al;Journal of Clinical Oncology;2024-08-20

5. Sample Size Calculation Under Nonproportional Hazards Using Average Hazard Ratios;Biometrical Journal;2024-08-12